Blanket Purchase Agreement 36C24222A0001

Award Date 10/1/21
Last Date to Order 9/30/26
Ultimate Awardee
Revvity Inc.
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) to Gen-Probe Incorporated, a medical diagnostics company, to provide tuberculosis (TB) testing supplies and reagents to the VA's Veterans Integrated Service Network (VISN) 1. The contract has a ceiling value of $100,000 and runs through November 19, 2025. Under this BPA, the VA has issued two task orders to date, valued at $10,146.18 and $19,957.43, for the delivery of AccuProbe TB reagents and...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 16 awarded a blanket purchase agreement to Quest Diagnostics Incorporated for T-SPOT.TB testing services. The agreement was issued against Quest Diagnostics' Medical Laboratory Testing and Analysis Services Federal Supply Schedule contract. Over multiple option years, task orders valued at $100.3K, $70.21K, $76.38K, and $100.3K were awarded to provide tuberculosis screening for veterans in...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA), Veterans Health Administration, Network Contracting Office 15 to Qiagen, LLC, a foreign-owned manufacturer of in-vitro diagnostic products. The $367,001.40 single-award BPA, with a performance period running through July 2028, is for the procurement of QuantiFERON TB Gold Plus Supplies. These products include TB test kits, controls, and accessories compatible with the Diasorin Liaison XL instrument...
The Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) to Biomerieux Inc., a global leader in in vitro diagnostics, to provide reagents and E-test strips. The contract has a ceiling value of $200,000 and a period of performance through September 30, 2025. This is a single-award BPA issued under the VA's Veterans Integrated Service Network 1 (VISN 1) to support the agency's clinical diagnostics and infectious disease testing requirements across its healthcare...
The Department of Veterans Affairs (VA) Veterans Health Administration Veterans Integrated Service Network (VISN) 22 has awarded a single-award Blanket Purchase Agreement (BPA) to Qiagen, LLC for the procurement of tuberculosis testing reagents. The BPA has a base year plus four option years to cover the supplies needed by VISN 22 healthcare facilities in California, Arizona, and New Mexico. Qiagen, LLC is an international provider of sample and assay technologies for molecular diagnostics,...
The U.S. Department of Veterans Affairs (VA), specifically the Veterans Integrated Service Network 23 (VISN 23), has awarded a Blanket Purchase Agreement (BPA) to Biomerieux Inc., a global leader in in vitro diagnostics, for the delivery of test kit reagents and associated diagnostic platforms. This single-award BPA, with a total ceiling value of $14,732,632.16, is part of Biomerieux's existing Federal Supply Schedule (FSS) contract for In Vitro Diagnostics, Reagents, and Test Kits. The...
This Blanket Purchase Agreement (BPA) was awarded by the Veterans Integrated Service Network 17 (VISN 17), a division of the U.S. Department of Veterans Affairs (VA), to Biomerieux Inc., a global leader in in vitro diagnostics. The single-award BPA, valued at up to $14.4 million over its 5-year period of performance, allows the VA to procure Biomerieux's proprietary BioFire diagnostic platforms, reagents, and test kits to support infectious disease testing and pathogen detection at VA healthcare...
The Department of Veterans Affairs (VA) Veterans Integrated Service Network 1 (VISN 1) has awarded a Blanket Purchase Agreement (BPA) contract to Immucor Inc., a manufacturer of in vitro diagnostic products and reagents. The BPA, valued at $295,907.80, is issued under Immucor's existing GSA Federal Supply Schedule contract for in vitro diagnostics, reagents, and tests. Through a series of BPA call orders, Immucor will provide specialized blood typing, compatibility, and antibody screening...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 16 awarded an indefinite delivery contract vehicle to Quest Diagnostics Incorporated for tuberculosis testing services. Under a single award contract with a potential value of $376,125 and period of performance through July 2025, Quest Diagnostics was issued four firm fixed price delivery orders totaling approximately $262,000 to provide Oxford Immunotec T-SPOT TB testing. Tests were to be...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) to Biomerieux Inc., a global leader in in vitro diagnostics. The single-award BPA, valued at up to $2,971,499.40, is for the supply of Biomerieux's proprietary reagents, diagnostic equipment, and associated maintenance services to the VA's VISN 17 network. The contract is established under the Federal Supply Schedule 65-VII for In Vitro Diagnostics, Reagents, and Test Kits, enabling the VA to...
  • 36C24222A0001
    Blanket Purchase Agreement
  • 4
    Federal Contract Awards

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 2 (VA VHA VISN 2) awarded a single-award Blanket Purchase Agreement (BPA) to Euroimmun US Incorporated, a subsidiary of Revvity Inc., to provide T-SPOT TB reagents. The BPA has a total ceiling value of $1,128,588.50 and runs through September 2026, with three call orders totaling over $400,000 issued to date. The T-SPOT TB reagents will support tuberculosis screening and diagnostic testing programs within the VA healthcare facilities in the New England region. As the prime contractor, Euroimmun US Incorporated will deliver the products from their facility in Marlborough, Massachusetts. No set-aside designations were used for these awards. The original sole-source procurement was justified based on the proprietary nature of the T-SPOT TB test, which is manufactured exclusively by Oxford Immunotec, a subsidiary of Revvity Inc.

Generated 9/28/24, 9:11 AM